Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Amplia Therapeutics (ATX)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
EBR Systems (EBR)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Patrys (PAB)
PYC Therapeutics
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
April 29th, 2025
Anteris - Share Price Down as Company Plans for Pivotal Global study in 2025
Read More
April 28th, 2025
EBR Systems Gains FDA-Approval for Cardiac Resynchronisation
Read More
April 28th, 2025
Neuren Confirms Endpoints for Phase III Study in PMS
Read More
April 28th, 2025
Oversold Biotechs – Deserved or Not?
Read More
April 26th, 2025
PYC Therapeutics Sets an Aggressive Clinical Agenda and Timeline
Read More
March 28th, 2025
Opthea Implodes
Read More
March 27th, 2025
Telix Gains Approval for First of Three Diagnostics for 2025
Read More
March 26th, 2025
Actinogen Medical: Progressing its Phase IIb/III Alzheimer's Study
Read More
March 26th, 2025
Syntara Accelerates Wound Healing Program
Read More
March 26th, 2025
Blinklab Initiates Lead-In to Pivotal Study for Autism Diagnostic Aid
Read More
March 6th, 2025
Chimeric Therapeutics Receives Sizeable Donation
Read More
March 5th, 2025
Telix Forecasts Minimum 50% Revenue Jump for 2025 to $1.2 billion
Read More
March 5th, 2025
Neuren Pharmaceuticals Continues to Build Cash Balance
Read More
March 5th, 2025
Clinuvel Pharmaceuticals Unveils 'Pavilion of Photomedicine' at AAD Meeting
Read More
March 3rd, 2025
Percheron Survives First Board Spill Attempt
Read More
March 3rd, 2025
Complete Response Rate of 57% in Imugene's Latest Azer-Cel Phase Ib Study
Read More
February 19th, 2025
Aroa Biosurgery Narrowly Misses Full-Year Guidance
Read More
February 18th, 2025
Immuron Sales Up 70% in First Half
Read More
February 18th, 2025
Leading the Way – Adalta's East to West Roadmap
Read More
February 17th, 2025
Opthea's Phase 3 Results Fast Approaching
Read More
Pages
1
2
3
4
5
6
7
8
9
